Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTUITIVE SURGICAL, INC.

(ISRG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Intuitive Surgical, Inc. : 43 Days Remain Before June 25, 2013, Lead Plaintiff Deadline in Intuitive Surgical, Inc., Securities Lawsuit, Hagens Berman Reminds Investors

05/13/2013 | 09:35am EST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, today reminded investors that 43 days remain before the June 25, 2013, lead plaintiff deadline in a securities class-action lawsuit brought against Intuitive Surgical, Inc. (NASDAQ: ISRG) ("ISRG" or "the company"). Those who have more than $300,000 in losses are encouraged to contact Hagens Berman Partner Reed Kathrein to discuss moving for lead plaintiff by emailing ISRG@hbsslaw.com or calling (510) 725-3000.

Investors who purchased ISRG common stock between Oct. 19, 2011, and April 18, 2013, (the "class period") and have suffered significant losses can also reach an attorney by visiting http://www.hb-securities.com/investigations/ISRG.

On April 26, 2013, a lawsuit was filed in the U.S. District Court for the Northern District of California, alleging that ISRG issued a series of false or misleading statements to investors during the class period. The suit alleges that ISRG failed to fully disclose to investors the financial impact of safety problems with its da Vinci Surgical System, including a number of deaths allegedly caused by the system.

On April 30, 2013, Medscape--an online medical resource for healthcare professionals--reported that the Food and Drug Administration has begun to investigate da Vinci following a spike in adverse event reports (AERs) related to the system's use in surgery. According to Medscape, the number of da Vinci AERs filed with the FDA increased by 34 percent between 2011 and 2012.

A number of lawsuits have been filed against the company seeking damages for injuries allegedly caused by da Vinci. ISRG's stock price suffered a significant decline following media coverage of those suits. The filed investor lawsuit claims that ISRG deceived investors regarding the risk of FDA action against the company.

Investors who wish to serve as lead plaintiff in the case must move the court no later than June 25, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
Mark@firmani.com


ę Business Wire 2013
All news about INTUITIVE SURGICAL, INC.
11/29INSIDER SELL : Intuitive Surgical
MT
11/22Intuitive Announces Executive Leadership Changes
AQ
10/21INTUITIVE SURGICAL : Morgan Stanley Adjusts Price Target on Intuitive Surgical to $325 fro..
MT
10/20INTUITIVE SURGICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
10/20Tranche Update on Intuitive Surgical, Inc.'s Equity Buyback Plan announced on February ..
CI
10/20INTUITIVE SURGICAL : Wells Fargo Adjusts Intuitive Surgical's Price Target to $381 from $3..
MT
10/20INTUITIVE SURGICAL : UBS Adjusts Price Target on Intuitive Surgical to $352 From $323 on I..
MT
10/20INTUITIVE SURGICAL : Deutsche Bank Adjusts Intuitive Surgical PT to $323 From $306, Mainta..
MT
10/19Intuitive Surgical 3Q Beats Analyst Views
DJ
10/19Intuitive Surgical Names Executives for Strategy and Growth, Global Business Services
DJ
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Financials (USD)
Sales 2021 5 676 M - -
Net income 2021 1 661 M - -
Net cash 2021 2 642 M - -
P/E ratio 2021 72,2x
Yield 2021 -
Capitalization 115 B 115 B -
EV / Sales 2021 19,8x
EV / Sales 2022 17,1x
Nbr of Employees 8 081
Free-Float 99,0%
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 321,63 $
Average target price 349,00 $
Spread / Average Target 8,51%
EPS Revisions
Managers and Directors
Gary S. Guthart President, Chief Executive Officer & Director
Marshall L. Mohr Chief Financial Officer & Executive Vice President
Calvin Darling Senior Director-Finance & Investor Relations
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors